Tovorafenib clinical trials
Also written TAK-580 and DAY101.
How each study uses tovorafenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tovorafenib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Apr 2024 · OJEMDA · NDA 217700 (FDA, Drugs@FDA)
- European Union
- 20 Apr 2026 · Ojemda · EMEA/H/C/006140 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2021 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 6
Day One Biopharmaceuticals, Inc. (4) · Millennium Pharmaceuticals, Inc. (3) · National Cancer Institute (NCI) (2) · Ipsen (1) · Karen D. Wright, MD (1) · Nationwide Children's Hospital (1) · Sabine Mueller, MD, PhD (1) · Daniel Morgenstern (1)
Often tested with
Tested in the same studies.
Vinblastine (1) · Pimasertib (1) · Plozalizumab (1) · Vedolizumab (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4, 1 in phase 3
Studies that test tovorafenib, phase 3 first.
- Jun 2027DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Phase 3 · Day One Biopharmaceuticals, Inc.
- Mar 2027Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsPhase 2 · Sabine Mueller, MD, PhD
- Mar 2027Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade GliomasEarly Phase 1 · Daniel Morgenstern
- May 2027A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid TumorsPhase 2 · Day One Biopharmaceuticals, Inc.
Studies
Open first, then newest update. How each study uses tovorafenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 14
- A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell HistiocytosisRecruitingPhase 2National Cancer Institute (NCI)NCT05828069Written as Tovorafenib
- Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)Not yet recruitingPhase 2Nationwide Children's HospitalNCT07206849Written as Tovorafenib
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaRecruitingPhase 1/2National Cancer Institute (NCI)NCT06965114Written as Tovorafenib
- Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsRecruitingPhase 2Sabine Mueller, MD, PhDNCT05465174Written as Tovorafenib
- Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade GliomasRecruitingEarly Phase 1Daniel MorgensternNCT06381570Written as Tovorafenib
- A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid TumorsRecruitingPhase 2Day One Biopharmaceuticals, Inc.NCT04775485Written as Tovorafenib
- DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)Active, not recruitingPhase 3Day One Biopharmaceuticals, Inc.NCT05566795Written as Tovorafenib
- A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain TumoursActive, not recruitingPhase 1IpsenNCT07441707Written as Tovorafenib
- DAY101 In Gliomas and Other TumorsCompletedPhase 1Karen D. Wright, MDNCT03429803Written as DAY101
- Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid TumorsTerminatedPhase 2Day One Biopharmaceuticals, Inc.NCT04985604Written as Tovorafenib
- Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsTerminatedPhase 1Day One Biopharmaceuticals, Inc.NCT07121829Written as Tovorafenib
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02723006Written as TAK-580
- Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic MelanomaCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT01425008Written as MLN2480
- A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02327169Written as MLN2480
Codes
What other systems call tovorafenib · ClinicalTrials.gg INT000905
- MeSH (NLM) C000626518tovorafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) ZN90E4027MTOVORAFENIBConfirmed FDA, NLM
- NCI Thesaurus C106254TovorafenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000626518 | tovorafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | ZN90E4027M | TOVORAFENIB | Confirmed FDA, NLM |
| NCI Thesaurus | C106254 | Tovorafenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.